Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 35Carcinoma, Non-Small-Cell Lung 27Breast Neoplasms 15Lung Neoplasms 13Neoplasm Metastasis 12Triple Negative Breast Neoplasms 11Neoplasms 10Colorectal Neoplasms 8Squamous Cell Carcinoma of Head and Neck 4Parkinson Disease 4, Autosomal Dominant Lewy Body 4Head and Neck Neoplasms 4Carcinoma, Pancreatic Ductal 4Stomach Neoplasms 3Neoplasms by Site 3Gastrointestinal Neoplasms 3Carcinoma 3Adenocarcinoma 3Vaccinia 2Rectal Neoplasms 2Ovarian Neoplasms 2Neoplasms by Histologic Type 2Gallbladder Neoplasms 2Fallopian Tube Neoplasms 2Esophageal Squamous Cell Carcinoma 2Endometrial Neoplasms 2Colonic Neoplasms 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Thymoma 1

Interventions

trifluridine tipiracil drug combination 1reolysin 1atezolizumab 1Gemcitabine 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anal Cancer Metastatic × 130-nm albumin-bound paclitaxel × 90 days × Clear all
NCT07280377 2026-05-19

GOBLET

Oncolytics Biotech

Phase 1/2 Active not recruiting
122 enrolled
Gastrointestinal

Anal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡